Suppr超能文献

右心室流出道重建的过去、现在及未来选择

Past, present, and future options for right ventricular outflow tract reconstruction.

作者信息

Carrel Thierry

机构信息

Department of Cardiac Surgery, University Hospital Zürich, Zürich, Switzerland.

出版信息

Front Surg. 2023 Jun 2;10:1185324. doi: 10.3389/fsurg.2023.1185324. eCollection 2023.

Abstract

The pulmonary valve is the most frequently replaced cardiac valve in congenital heart diseases. Whether the valve alone or part of the right ventricular outflow tract have to be repaired or replaced depends on the specific pathological anatomy of the malformation. Once the decision to replace the pulmonary valve has been made, two options are available: the isolated transcatheter pulmonary valve replacement and the surgical implantation of a prosthetic valve either isolated or in combination with a procedure on the right ventricular outflow tract. In this paper, we will focus on the different past and present surgical options and present a new concept called "endogenous tissue restoration," a promising alternative to the hitherto existing implants. From a general point of view, neither the transcatheter nor the surgical valvular implants are magic bullets in the arsenal for the management of valvular diseases. Smaller valves have to be frequently replaced because of outgrowth of the patients, larger tissue valves may present late structural valve deterioration, while xenograft and homograft conduits may calcify and therefore become narrowed within unpredictable incidence and interval following implantation. Based on long-term research efforts combining the knowledge of supramolecular chemistry, electrospinning, and regenerative medicine, endogenous tissue restoration has emerged most recently as a promising option to create long-term functioning implants. This technology is appealing because following resorption of the polymer scaffold and timely replacement through autologous tissue, no foreign material remain at all in the cardiovascular system. Proof-of-concept studies as well as small first-in-man series have been completed and have demonstrated favorable anatomic and hemodynamic results, comparable to currently available implants in the short term. Based on the initial experience, important modifications to improve the pulmonary valve function have been initiated.

摘要

肺动脉瓣是先天性心脏病中最常被置换的心脏瓣膜。是仅置换瓣膜还是需要修复或置换右心室流出道的一部分,取决于畸形的具体病理解剖结构。一旦决定置换肺动脉瓣,有两种选择:单纯经导管肺动脉瓣置换术以及外科植入人工瓣膜,可单独植入或与右心室流出道手术联合进行。在本文中,我们将重点关注过去和现在不同的外科手术选择,并提出一种名为“内源性组织修复”的新概念,这是一种有前景的替代现有植入物的方法。从总体来看,经导管瓣膜植入物和外科瓣膜植入物都不是治疗瓣膜疾病的万能方法。较小的瓣膜由于患者生长发育需要经常更换,较大的组织瓣膜可能会出现晚期结构性瓣膜退变,而异体移植物和同种异体移植物导管可能会钙化,因此在植入后会在不可预测的发生率和时间间隔内变窄。基于将超分子化学、电纺丝和再生医学知识相结合的长期研究成果,内源性组织修复最近已成为一种有前景的制造长期功能性植入物的选择。这项技术很有吸引力,因为在聚合物支架吸收后通过自体组织及时替代,心血管系统中不会残留任何异物。概念验证研究以及小型首例人体试验系列已经完成,并且在短期内显示出与现有植入物相当的良好解剖和血流动力学结果。基于初步经验,已经开始进行重要改进以改善肺动脉瓣功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a198/10272445/0b7719a5c069/fsurg-10-1185324-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验